Integrative Cancer Care and the Art of Medicine
The lead article in this issue is by Dr. Steven Greer, one of the world's most widely recognized experts in psychooncology, whose studies of mental adjustment to cancer have proved seminal in much of today's research in the psychology of cancer. His article is dedicated to Dr. Bernard Fox, himself a truly seminal figure in the field. Dr. Fox, who died in October of 2001, was one of the first scientists to encourage research in this area. As an epidemiologist and biostatistician, he was committed to making sure that psychooncology research was of high quality, and his critiques in this field were critical to maintaining its credibility. He was a founding member of the International Psychooncology Society and received its Sutherland Memorial Award in 1986. We are pleased to be able to afford Dr. Greer the opportunity to acknowledge him. Greer's contribution itself provides an overview of the biopsychosocial model of psychooncology, and the humanizing and healing role that conscious attention to the patient as a being of soma and spirit can bring to our practice of care, surely a most important feature of the art of medicine.
Two graduates of the PhD program in Medicinal Chemistry and Pharmacognosy of the University of Illinois at Chicago College of Pharmacy have teamed with associate editor Charlotte Gyllenhaal and myself to review the literature on the potential role of ginseng in cancer therapy. Decisions about the use of a botanical such as ginseng with cancer patients are difficult to make based on available evidence. In general, the toxicity of ginseng seems to be low, and reports of the "ginseng abuse syndrome" appear to be based largely on consumers who took other psychoactive substances along with products characterized as ginseng but never analyzed phytochemically to document their identity. Reports of antistress and antifatigue activity abound in the animal literature. However, the human studies of effects of ginseng on stress and fatigue are still, overall, inconclusive, although some recent studies of ginseng effects on memory are intriguing. A particular problem with these studies is that none of the more recent studies examine the effects of ginseng on fatigue in cancer patients-and, of course, the evaluation of fatigue in cancer patients itself is still fraught with technical problems. More generally, though, very few of the human studies even examine ginseng in populations of older adults or those convalescing from illness, which are the populations for whom ginseng is recommended in traditional Chinese medicine. Studies showing beneficial effects of ginseng or its constituents on cancer are also common in the in vitro and animal literature. Intriguing recent studies point to an ability to help moderate blood sugar levels, a potential activity that increases in importance as we learn more about the relationship of insulin and cancer. Yet human studies on ginseng are almost nonexistent, although there are a few preliminary studies of cancer-preventive effects of ginseng. Finally, it is clear from analyses of ginseng products from around the world that quality control of this often costly herb has not been ideal. If we allow or encourage our patients to take ginseng, do we know whether they will actually get any active ginsenosides?
On the other hand, many cancer patients have found benefit from using ginseng. Ginseng is recommended for cancer patients undergoing chemotherapy by Dr. James Gordon of the Center for Mind-Body Medicine (and an advisory board member and contributor to this journal), as quoted in a recent issue of Smithsonian magazine. 1 Gordon notes in this article the difficulties in obtaining ginseng products of high quality. Ginseng is a frequent constituent of prescriptions of "tonic" herbs for cancer patients. Its many fascinating laboratory results make it appear to be a very attractive botanical supplement for cancer patients and those concerned about cancer risk (we suspect that readers of the article, with or without cancer, will probably want to go right out and buy a good quality ginseng preparation themselves!). Given the apparent safety in most patients, if usual guidelines for use are followed, is it possible to make a recommendation of a trial of ginseng to the fatigued cancer patient for whom other antifatigue strategies are not working?
Use of botanicals and other supplements for which data on human health effects are incomplete is still a decision that the physician will have to make himself or herself, in discussions with patients. Certainly if we rely exclusively on an evidence-based medicine analysis of ginseng we will discourage patients from using it. Just as certainly, if we decide to wait for the conclusive evidence-based evaluation of all of ginseng's potential therapeutic effects, both we and our patients will have passed on to a higher plane of existence by the time it becomes available! If this happens, we run the risk of not encouraging our patients to access a substance that could be quite beneficial to them. Decisions that must be made on the basis of insufficient knowledge are a plague in medicine, but are also inevitable, particularly for practitioners of integrative medicine at this time in its development. But we must nevertheless Editorial INTEGRATIVE CANCER THERAPIES 2(1); 2003 pp. 3-4 decide, and each physician will need to develop his or her own style for making such decisions. This need mandates that integrative physicians become educated in the complexities of botanical medicines and other supplements (or techniques) that are frequently used by patients. We need to do whatever we can to promote effective research studies on these potentially useful supplements. I would also counsel that doctors have a direct responsibility to ensure that supplements that our patients take are of the highest quality, and that it is our responsibility as physicians to take an active role in educating ourselves on these supplements and in promoting the development of supplement quality standards.
Susan Carter and colleagues give a very scientific perspective on the lost art of exercise as a means of promoting health and strength among those suffering from cancer. Concentrating on the patient, these authors present a case study of a cancer patient undergoing exercise therapy. The Rocky Mountain Cancer Rehabilitation Institute, under the leadership of Carole Schneider, a productive member of this journal's editorial board, is making substantial progress in researching this increasingly important aspect of the physical care of cancer patients.
The Point-Counterpoint in this issue concerns an issue that lies at the heart of the art of medicine: how to give patients bad news. Based on an April, 2002, survey published in the Journal of Clinical Oncology, we have gathered responses from two conventionally practicing oncologists, Drs. Frances Collichio and Lidia Schapira, and two integrative oncologists, Drs. Terry Bugno and Jeremy Geffen. This sensitive issue is probed from many different directions by this very interesting team. Because oncology has so many situations where doctors give bad news to patients, this article is one that should be required reading for all cancer clinicians.
In our Integrative Tumor Board, which concerns a patient with early stage prostate cancer, we approach even more directly the "art" of medicine: Daniel Monti and Caroline Peterson of the Center for Integrative Medicine discuss the use of a new psychological care model, Mindfulness-Based Art Therapy (MBAT). MBAT is now being studied in groups of prostate cancer patients at the Center in a randomized trial funded by the National Institutes of Health. We are also lucky to have contributions from Susan Bauer-Wu and Stacy Kennedy of the Zakim Center for Integrative Medicine at Harvard. Bauer-Wu discusses complementary treatments for hot flashes, and Kennedy presents a nutritional analysis of prostate cancer. Gordon Saxe, who organized a pilot clinical trial of a macrobioticsbased diet with mindfulness meditation training, provides an excellent overview of the role of diet in the context of conventional treatment for prostate cancer. Finally, Z'ev Rosenberg of the Pacific College of Oriental Medicine discusses traditional Chinese herbal medicine formulas for prostate cancer, also with some interesting dietary perspectives.
